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post-hemodialysis target blood pressure7 may therefore
paradoxically decrease life expectancy rather than prolong
it.
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To the Editor: Hallelujah! The long anticipated results of the
Dialysis Clinical Outcomes Revisited (DCOR) trial are finally
published.1 To our surprise, despite triumphant press releases
and hyperbolic pronouncements made in industry-sponsored
symposia at nephrology meetings 2 years ago, the DCOR
study actually found no mortality benefit among hemodia-
lysis patients treated with sevelamer as compared with
patients treated with CCPBs (calcium-containing phosphate
binders). At once, the NKF-KDOQI/KDIGO opinion-based
recommendations regarding the possible advantages of the
non-calcium, non-aluminum resin-based phosphate binder,
sevelamer become moot. In these guidelines, the postulated
rationale for preferential use of non-calcium binders in
certain clinical circumstances was based on observational
studies showing an association between the use of CCPB
and mortality risk or intervention trials employing surrogate
end points such as cardiovascular calcification.2,3 These
important results from DCOR imply that clinicians can now
confidently prescribe effective and substantially less expensive
CCPB therapy unburdened by prior expert ‘opinion’
suggesting that CCPBs represent arcane and potentially
cardiotoxic therapy. Case closed, right? Well probably not.
Although statistically invalid given the negative results for the
primary outcomes (all-cause and cardiovascular mortality),
the authors conducted a post hoc analysis to study the effect
of patient age on the results. A major case is made for a
possible benefit on all-cause mortality in subjects aged over
65 years treated with sevelamer. This post hoc analysis will
undoubtedly become fodder for pharmaceutical company
marketing and quite possibly will be used to justify additional
opinion-based recommendations for preferential use of
sevelamer in the older dialysis patient population. However,
we are quite concerned about incomplete reporting of the
results of the DCOR study. The reported dropout rate (49%)
is extremely high and unacceptable given the simplicity of the
DCOR study design. DCOR is a mortality study that enrolled
only Medicare-eligible dialysis patients. Although study
subjects may withdraw consent for participation, an intent-
to-treat analysis of all enrolled subjects is feasible, as there
are only three possible outcomes regarding mortality (alive
on dialysis, alive after kidney transplant, or dead). Although
data are not reported, the authors mention that an intent-
to-treat analysis of all-cause mortality employing the Centers
for Medicare and Medicaid Services (CMS) database also
showed no difference in all-cause mortality. Did the
postulated age-related difference in mortality persist in this
intent-to-treat data set? Full reporting of intent-to-treat data
analysis should have been a prerequisite for publication and
remains mandatory for any meaningful analysis of DCOR
results.
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The case against calcium-based binders has been accumu-
lating for years.1 The presence, and extent, of vascular
calcifications are strong predictors of cardiovascular and
all-cause mortality.2,3 The dose of calcium-based phosphate
binders (acetate or carbonate) has been linked to the
severity of vascular calcification.2,4 As a result of these
observations, the US National Kidney Foundation had
issued guidelines calling for lower serum phosphorus and
calcium targets in dialysis patients, limitation of the dose
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